Repligen Co. (NASDAQ:RGEN) Shares Sold by Fred Alger Management LLC

Fred Alger Management LLC lowered its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 9.8% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 359,507 shares of the biotechnology company's stock after selling 39,047 shares during the period. Fred Alger Management LLC owned approximately 0.64% of Repligen worth $51,747,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Bridgefront Capital LLC acquired a new position in shares of Repligen in the fourth quarter valued at approximately $562,000. Bayesian Capital Management LP acquired a new position in Repligen during the 4th quarter worth approximately $947,000. Algert Global LLC acquired a new position in Repligen during the 4th quarter worth approximately $844,000. Alyeska Investment Group L.P. acquired a new position in Repligen during the 4th quarter worth approximately $53,428,000. Finally, Itau Unibanco Holding S.A. acquired a new position in Repligen during the 4th quarter worth approximately $40,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have commented on RGEN. JPMorgan Chase & Co. lowered their price target on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a report on Tuesday, April 29th. Canaccord Genuity Group lowered their price target on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a report on Wednesday, April 16th. HC Wainwright reiterated a "buy" rating and set a $180.00 price target on shares of Repligen in a report on Monday, May 5th. Wolfe Research upgraded shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price for the company in a report on Tuesday, April 29th. Finally, Evercore ISI assumed coverage on shares of Repligen in a research report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 target price on the stock. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $173.25.

Insider Activity

In other news, Director Margaret Pax purchased 250 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This trade represents a 31.53% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.20% of the company's stock.

Repligen Stock Performance

RGEN traded down $1.04 on Tuesday, reaching $132.68. The company had a trading volume of 306,837 shares, compared to its average volume of 727,328. The stock has a 50-day moving average price of $134.55 and a 200-day moving average price of $145.43. Repligen Co. has a 1 year low of $102.97 and a 1 year high of $182.52. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $7.45 billion, a PE ratio of -260.16, a P/E/G ratio of 4.54 and a beta of 1.21.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. During the same period in the prior year, the company earned $0.28 earnings per share. The business's revenue was up 10.4% compared to the same quarter last year. As a group, research analysts forecast that Repligen Co. will post 1.72 EPS for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.